Ultragenyx Pharmaceutical (NASDAQ:RARE) and Immunome (NASDAQ:IMNM) Head-To-Head Contrast

Immunome (NASDAQ:IMNM) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.

Volatility and Risk

Immunome has a beta of 2.13, suggesting that its share price is 113% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.

Earnings & Valuation

This table compares Immunome and Ultragenyx Pharmaceutical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	N/A	N/A	-$212.39 million	($2.53)	-9.47
Ultragenyx Pharmaceutical	$673.00 million	2.13	-$575.00 million	($5.84)	-2.48

Immunome has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Immunome is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Immunome and Ultragenyx Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Immunome and Ultragenyx Pharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1	0	13	0	2.86
Ultragenyx Pharmaceutical	1	10	9	1	2.48

Immunome presently has a consensus target price of $34.42, suggesting a potential upside of 43.58%. Ultragenyx Pharmaceutical has a consensus target price of $34.58, suggesting a potential upside of 138.31%. Given Ultragenyx Pharmaceutical’s higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Immunome.

Institutional and Insider Ownership

44.6% of Immunome shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 7.2% of Immunome shares are held by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Immunome beats Ultragenyx Pharmaceutical on 8 of the 14 factors compared between the two stocks.

About Immunome

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.